Mineralys Therapeutics【MLYS】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

12.34

買値

11.40

売値

15.25

出来高

512,659

11.55 日の範囲 12.50

7.29 52 週間の範囲 16.905

時価総額

614.145M

前日終値

11.83

始値

11.73

時刻

339

12.34

(priorref)

最終取引時間

財務取引量

US$ 6,115,798

VWAP

11.9296

平均取引量 (3 か月)

174,016

発行済株式数

49,768,669

配当利回り

PER

-8.54

1 株当たり利益 (EPS)

-1.44

歳入

純利益

-71.9M

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in... Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.mineralystx.com

本社

Wilmington, Delaware, USA

設立

Mineralys Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker MLYS. The last closing price for Mineralys Therapeutics was US$11.83. Over the last year, Mineralys Therapeutics shares have traded in a share price range of US$ 7.29 to US$ 16.905.

Mineralys Therapeutics currently has 49,768,669 shares in issue. The market capitalisation of Mineralys Therapeutics is US$588.76 million. Mineralys Therapeutics has a price to earnings ratio (PE ratio) of -8.54.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate...

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...

Form 8-K - Current report

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal...

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...

Form 8-K - Current report

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.35	2.91909924937	11.99	12.57	11.19	101720	11.93297886	CS
4	0.35	2.91909924937	11.99	14.19	11.19	144011	12.78599062	CS
12	0.24	1.98347107438	12.1	15.25	11.19	174016	13.31232878	CS
26	0.59	5.02127659574	11.75	15.25	8.58	198077	12.56491444	CS
52	4.46	56.5989847716	7.88	16.905	7.29	175363	12.63800781	CS
156	-8.76	-41.5165876777	21.1	21.98	5.85	185588	12.89322856	CS
260	-8.76	-41.5165876777	21.1	21.98	5.85	185588	12.89322856	CS

MLYS - Frequently Asked Questions (FAQ)

What is the current Mineralys Therapeutics share price?

The current share price of Mineralys Therapeutics is US$ 12.34

How many Mineralys Therapeutics shares are in issue?

Mineralys Therapeutics has 49,768,669 shares in issue

What is the market cap of Mineralys Therapeutics?

The market capitalisation of Mineralys Therapeutics is USD 588.76M

What is the 1 year trading range for Mineralys Therapeutics share price?

Mineralys Therapeutics has traded in the range of US$ 7.29 to US$ 16.905 during the past year

What is the PE ratio of Mineralys Therapeutics?

The price to earnings ratio of Mineralys Therapeutics is -8.54

What is the reporting currency for Mineralys Therapeutics?

Mineralys Therapeutics reports financial results in USD

What is the latest annual profit for Mineralys Therapeutics?

The latest annual profit of Mineralys Therapeutics is USD -71.9M

What is the registered address of Mineralys Therapeutics?

The registered address for Mineralys Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Mineralys Therapeutics website address?

The website address for Mineralys Therapeutics is www.mineralystx.com

Which industry sector does Mineralys Therapeutics operate in?

Mineralys Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MYSZMy Size Inc	US$ 4.2001 (211.12%)	121.03M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	78.06M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	34M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.94k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	121.95M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.5M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.63M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.84M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	8.58M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	5.96M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.33M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	310.19M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	306.25M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	293.22M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	281.23M